SCHEMBL21325056

SCHEMBL21325056

CC(C)(C)c1nncc2c(OCC3CC3)c(F)ccc12

nearest known ligand 0.34

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ ALOX5AP P20292 3/20 0.34
▸ FEN1 P39748 3/20 0.34
▸ RIPK1 Q13546 1/20 0.32
▸ CYP11B1 P15538 1/20 0.32
▸ CYP11B2 P19099 1/20 0.32
▸ FFAR4 Q5NUL3 3/20 0.30
▸ EP300 Q09472 1/20 0.30
▸ CNR1 P21554 1/20 0.30
▸ CNR2 P34972 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21325503 0.82 FFAR4 (0.33) ALOX5APFEN1RIPK1FFAR4CNR2
SCHEMBL21325060 0.79 ALOX5AP (0.33) ALOX5APFEN1RIPK1CYP11B1CYP11B2
SCHEMBL21325058 0.79 FFAR4 (0.35) ALOX5APFEN1RIPK1FFAR4EP300
SCHEMBL21325055 0.76 RIPK1 (0.33) ALOX5APFEN1RIPK1
SCHEMBL20204677 0.74 PDE2A (0.37) ALOX5APFEN1FFAR4
SCHEMBL21325057 0.73 RIPK1 (0.37) ALOX5APFEN1RIPK1
SCHEMBL21690529 0.72 ALOX5AP (0.34) ALOX5APFEN1CYP11B1CYP11B2FFAR4
SCHEMBL21690530 0.72 FFAR4 (0.38) ALOX5APFEN1FFAR4
SCHEMBL21325050 0.71 HTR2B (0.35) ALOX5APFEN1RIPK1FFAR4CNR2
SCHEMBL20202029 0.68 RIPK1 (0.33) ALOX5APFEN1RIPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11247984-B2 Uracil containing compounds CV6 THERAPEUTICS (NI) LIMITED (GB) 2022-02-15 — — US disclosed
US-11174271-B2 6-membered uracil isosteres CV6 THERAPEUTICS (NI) LIMITED (GB) 2021-11-16 — — US disclosed
US-11168059-B2 Amino sulfonyl compounds CV6 THERAPEUTICS (NI) LIMITED (GB) 2021-11-09 — — US disclosed
US-10858344-B2 Hydantoin containing deoxyuridine triphosphatase inhibitors CV6 THERAPEUTICS (NI) LIMITED (GB) 2020-12-08 — — US disclosed
US-20200039966-A1 URACIL CONTAINING COMPOUNDS CV6 THERAPEUTICS (NI) LIMITED (GB) 2020-02-06 — — US disclosed
US-20190330158-A1 AMINO SULFONYL COMPOUNDS CV6 THERAPEUTICS (NI) LIMITED (GB) 2019-10-31 — — US disclosed
US-20190330210-A1 HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS CV6 THERAPEUTICS (NI) LIMITED (GB) 2019-10-31 — — US disclosed
US-20190270756-A1 6-MEMBERED URACIL ISOSTERES CV6 THERAPEUTICS (NI) LIMITED (GB) 2019-09-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11174271-B2 6-membered uracil isosteres UNG, DUT, DPYD ALOX5AP 3330/4885FEN1 52/4885RIPK1 3321/4885
US-20190330210-A1 HYDANTOIN CONTAINING DEOXYURIDINE TRIPHOSPHATASE INHIBITORS DUT, TYMP, DPYD ALOX5AP 2919/4885FEN1 108/4885RIPK1 3869/4885
US-10858344-B2 Hydantoin containing deoxyuridine triphosphatase inhibitors DUT, TYMP, DPYD ALOX5AP 2919/4885FEN1 108/4885RIPK1 3869/4885
US-11168059-B2 Amino sulfonyl compounds DPYD, DNPEP, DUT ALOX5AP 4132/4885FEN1 256/4885RIPK1 3529/4885
US-20190330158-A1 AMINO SULFONYL COMPOUNDS DPYD, DNPEP, DUT ALOX5AP 4132/4885FEN1 256/4885RIPK1 3529/4885
US-20200039966-A1 URACIL CONTAINING COMPOUNDS UNG, DPYD, DUT ALOX5AP 2695/4885FEN1 21/4885RIPK1 3431/4885
US-11247984-B2 Uracil containing compounds UNG, DPYD, DUT ALOX5AP 2695/4885FEN1 21/4885RIPK1 3431/4885
US-20190270756-A1 6-MEMBERED URACIL ISOSTERES UNG, DUT, DPYD ALOX5AP 3330/4885FEN1 52/4885RIPK1 3321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback